DexCom (DXCM) Earnings Date & Reports

Key Takeaways

• DexCom reported third quarter 2026 revenue of $1.34 billion, up 11% year over year on both a reported and organic basis.
• Adjusted (non-GAAP) earnings per share came in at $0.73, beating the analyst consensus estimate of $0.67 by roughly 8%.
• U.S. revenue grew 14% to about $970 million, while international revenue rose 5% to roughly $375 million.
• Management raised its full-year 2026 revenue guidance to $5.20–$5.25 billion, implying 12%–13% growth.
• Non-GAAP operating margin expanded to approximately 24%, and adjusted EBITDA margin reached about 32%.
• Shares climbed roughly 2% in after-hours trading following the release.
• For more on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for deeper coverage.
• Discover Trending AI Robots to see how AI-driven strategies are navigating the current market.

Earnings Context and Why It Matters

DexCom is a leading maker of continuous glucose monitoring (CGM) systems used by people with diabetes to track glucose levels in real time without routine fingersticks. Its quarterly results are closely watched as a barometer of demand for diabetes technology and of the company's push to expand CGM access into broader patient populations. Following a strong first half of 2026, investors were focused on whether DexCom could sustain double-digit growth, defend its market share, and continue improving profitability. The third quarter also carried significance because management's outlook and commentary on reimbursement expansion—particularly potential Medicare coverage for people with type 2 diabetes who do not use insulin—can meaningfully shape expectations for the company's long-term addressable market.

Reported Results

For the third quarter ended September 30, 2026, DexCom posted total revenue of $1.34 billion, an increase of 11% compared with $1.21 billion in the same period a year earlier. U.S. revenue reached approximately $970 million, up 14%, while international revenue totaled about $375 million, up 5%. Management attributed the slower international growth to difficult comparisons against reimbursement wins from the prior year rather than underlying market weakness.

On the bottom line, the company reported adjusted (non-GAAP) earnings per share (EPS) of $0.73, exceeding the consensus estimate of $0.67. GAAP (Generally Accepted Accounting Principles) diluted EPS was $0.72. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) came in at $435.2 million, above the roughly $424 million analysts expected. Non-GAAP operating margin expanded to approximately 24%, reflecting manufacturing efficiencies, improved freight costs, and the growing contribution of the G7 15-day extended-wear sensor.

DexCom also raised its full-year 2026 revenue outlook to $5.20–$5.25 billion, up from $5.18–$5.25 billion previously, and tightened its profitability targets, including non-GAAP operating margin guidance of approximately 24%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are monitoring earnings season or tracking momentum across sectors, the AI Screener offers a structured way to narrow a broad universe of securities. Consider exploring it to complement your research workflow.

Market Reaction and Investor Sentiment

The market responded positively to DexCom's third quarter results, with shares rising roughly 2% in after-hours trading following the October 29 release. The upbeat reaction reflected a combination of an earnings beat, a modest revenue beat, and an upward revision to full-year guidance. Investors appeared to interpret the results as evidence that DexCom's growth algorithm remains intact even as it laps challenging prior-year comparisons in international markets.

Sentiment also drew support from management's commentary on reimbursement momentum. Executives reiterated that the company expects a Centers for Medicare & Medicaid Services (CMS) coverage decision for people with type 2 diabetes who do not use insulin this year, with potential implementation in mid-2027. That catalyst, together with the publication of the company's CONNECT clinical trial data in the New England Journal of Medicine, reinforced the longer-term bull case for expanded CGM access.

Forward Outlook and Key Factors to Monitor

Following the third quarter, several themes will likely shape investor attention in the quarters ahead. First, the pace of the G7 15-day rollout remains a key driver of both revenue and margins. Management expects to convert nearly half of its U.S. customer base to the extended-wear sensor by the end of 2026, with international launches beginning in Canada in November 2026 and Japan expected in early 2027.

Second, reimbursement expansion is a major catalyst to watch. A CMS coverage decision for non-insulin-using people with type 2 diabetes could substantially widen DexCom's addressable market, and investors will monitor the timing and terms of any announcement, as well as the expected implementation in mid-2027.

Third, profitability trends deserve continued scrutiny. Management guided to a non-GAAP operating margin of roughly 24% for 2026 and indicated it expects further margin progression into 2027, supported by manufacturing efficiencies and the normalization of startup costs at its new Ireland facility.

Finally, the product pipeline, including the next-generation G8 sensor expected in late 2027 or early 2028, and the over-the-counter Stelo platform, represent longer-term growth levers. Balancing these opportunities against ongoing foreign-exchange headwinds and competitive dynamics in the CGM market will be central to how investors evaluate DexCom's trajectory going forward.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations